A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome | Zendy

Guillem Clot | Zendy; Pedro Jares | Zendy; Eva Giné | Zendy; Alba Navarro | Zendy; Cristina Royo | Zendy; Magda Pinyol | Zendy; David MartinGarcía | Zendy; Santiago Demajo | Zendy; Blanca Espinet | Zendy; Antonio Salar | Zendy; Ana Ferrer | Zendy; Ana Muntañola | Zendy; Marta Aymerich | Zendy; Hilka RauertWunderlich | Zendy; Elaine S. Jaffe | Zendy; Joseph M. Connors | Zendy; Randy D. Gascoyne | Zendy; Jan Delabie | Zendy; Armando LópezGuillermo | Zendy; German Ott | Zendy; George W. Wright | Zendy; Louis M. Staudt | Zendy; Andreas Rosenwald | Zendy; David W. Scott | Zendy; Lisa M. Rimsza | Zendy; Sı́lvia Beà | Zendy; Elı́as Campo | Zendy

AI Assistant Blog Pricing

Open Access

A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome

Author(s) -

Guillem Clot,

Pedro Jares,

Eva Giné,

Alba Navarro,

Cristina Royo,

Magda Pinyol,

David MartinGarcía,

Santiago Demajo,

Blanca Espinet,

Antonio Salar,

Ana Ferrer,

Ana Muntañola,

Marta Aymerich,

Hilka RauertWunderlich,

Elaine S. Jaffe,

Joseph M. Connors,

Randy D. Gascoyne,

Jan Delabie,

Armando LópezGuillermo,

German Ott,

George W. Wright,

Louis M. Staudt,

Andreas Rosenwald,

David W. Scott,

Lisa M. Rimsza,

Sı́lvia Beà,

Elı́as Campo

Publication year - 2018

Publication title -

blood

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.515

H-Index - 465

eISSN - 1528-0020

pISSN - 0006-4971

DOI - 10.1182/blood-2018-03-838136

Subject(s) - mantle cell lymphoma , lymphoma , outcome (game theory) , gene signature , signature (topology) , biology , computational biology , cancer research , bioinformatics , oncology , gene , medicine , genetics , immunology , gene expression , mathematics , geometry , mathematical economics

Key Points A new molecular assay identifies conventional and leukemic nonnodal MCL with differing clinicobiological features. The integration of the novel assay with genetic alterations identifies subsets of MCL patients with different management and outcome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog